Rilotumumab
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Rilotumumab
- DrugBank Accession Number
- DB11972
- Background
Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- AMG 102
- Rilotumumab
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Rilotumumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Rilotumumab. Aducanumab The risk or severity of adverse effects can be increased when Rilotumumab is combined with Aducanumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilotumumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Rilotumumab. Amivantamab The risk or severity of adverse effects can be increased when Rilotumumab is combined with Amivantamab. Ansuvimab The risk or severity of adverse effects can be increased when Rilotumumab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Rilotumumab. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Rilotumumab. Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rilotumumab. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 51WEW898IJ
- CAS number
- 872514-65-3
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911263
- Wikipedia
- Rilotumumab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Terminated Treatment Malignant Neoplasm of Stomach 2 2 Completed Treatment Advanced Malignant Glioma 1 2 Completed Treatment Advanced Renal Cell Carcinoma 1 2 Completed Treatment Glioblastoma Multiforme (GBM) / Gliosarcoma 1 2 Completed Treatment Malignant Neoplasm of Esophagus / Malignant Neoplasm of Stomach 1 2 Completed Treatment Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma 1 2 Withdrawn Treatment Advanced Malignant Mesothelioma / Epithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma 1 2, 3 Terminated Treatment MET Positive / Recurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma AJCC v7 1 1 Completed Treatment Part 1- Advanced Solid Tumors / Part 2- Advanced or Metastatic Gastric Cancer / Part 2- Advanced or Metastatic GEJ 1 1, 2 Completed Treatment Adenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers / Malignant Neoplasm of Stomach 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on October 20, 2016 21:07 / Updated on February 21, 2021 18:53